Market Insights
The global chronic idiopathic constipation (CIC) drugs market is moderately competitive and is characterized by an excellent demand for over-the-counter medications. Considering CIC as a symptom and not a disorder, patients tend to optf-medication through OTC drugs. This report on the CIC drugs market studies, estimates, and forecasts the market for various drugs for treating chronic idiopathic constipation. The global CIC drugs market report studies this market for drug types, prescription types, and geographical distribution.
In terms of drug type, the global CIC market is studied for Lubiprostone, Linaclotide, and other drugs. The market size and forecast for these segments are provided for 2014-2022, with respective CAGRs for 2016-2022, while considering 2015 as the base year. In addition, this report also studies the market prospects for Plecanatide and Elobixibat, the phase 3 CIC drugs.
The prescription-based market for CIC drugs is classified as the prescribed CIC drugs market and OTC CIC drugs markets. The prescribed drugs market is further categorized into branded defined and generic prescribed CIC drugs segments. Finally, the market size and forecast are provided for these segments for 2014-2022, with respective CAGRs for 2016-2022.
This report includes qualitative market analysis tools such as attractive investment proposition, market dynamics, and competition mapping. The report concludes with a mapping of the key CIC drug manufacturers operating in the global CIC drugs market.
Chronic Idiopathic Constipation (CIC) is characterized by the chronic presence of constipation symptoms due to unknown causes and not due to any underlying illness or an effect of medication. 16% to 17% of adults in Europe and US suffer from constipation. Chronic constipation is more common among women and older adults over 65. Among these, 80% of institutionalized geriatrics are reported to suffer from chronic constipation.
The global chronic idiopathic constipation drugs market is expected to undergo significant growth in the next few years due to the phenomenal growth in disease prevalence and geriatric population pool, which has led to the growing adoption of CIC drugs. In addition, FDA approvals and ongoing successful clinical trials drive this market towards growth. Moreover, the growing geriatric population and rise in healthcare spending across developed and developing regions are creating potential scope for the global CIC drugs market.
North America contributes the most to the CIC drugs market by over-the-counter (OTC) drugs. There is a huge demand for prescribed constipation drugs in developed markets of the US, Germany, France, Spain, and others. Bisacodyl, Senna, and polyethylene glycol are some of the major OTC drugs widely adopted worldwide.
Future regulatory approvals for Elobixibat and Plecanatide are expected to create further growth opportunities in the market. For instance, Lecanatide has successfully accomplished phase 3 trials for CIC treatment and is under further evaluation for IBS-C. Therefore, it is observed that the CIC market is open to different novel pharmacological solutions, thus exhibiting additional growth potential for market entrants.
CIC drugs assist in alleviating abdominal pain and straining and facilitating bowel movements in patients. Lubiprostone efficiently relieves these conditions and is also used for treating IBS-C. On the other hand, certain patient-specific side effects such as nausea, occasional stomach pain, tight throat, and others may hold back the demand for newer drugs. Thus the market players are increasingly focusing on introducing safer pharmacological alternatives.Growth in awareness about the disease and increased disease prevalence, particularly in the geriatric patient pool, has urged the need for prompt and safest possible CIC drugs. The CIC drugs market is estimated to reach USD 2.5 Bn by 2022, progressing at a CAGR of 6.4% during 2016-2022. Growth in demand for CIC drugs in developing markets of the Asia Pacific and the rest of the world serves as a significant opportunity for the market players intending to enhance their international footprint. The huge gap of unmet needs in the lesser developed economies coupled with growing healthcare awareness will serve as growth facilitators in these regions.Chronic Idiopathic Constipation (CIC) drugs are widely adopted across the world, particularly in the regions where the prevalence of the condition is higher. Lubiprostone, Linaclotide, and other laxatives are the major drugs used for CIC treatment.
The global CIC drugs market is dominated by Lubiprostone drugs, with more than 40% market share in 2014. However, due to its proven efficiency, established safety profile, and anticipated worldwide commercialization, the Linaclotide drugs segment is expected to register the highest growth rate at above 7% during 2016 – 2022. On the other hand, the lubiprostone drugs segment will decline due to its limited efficacy, patent loss, and sharp competition against Linaclotide drugs.Other drugs used to treat chronic constipation disease include Bisacodyl, Chronulac, Constulose, Duphalac, Enulose (lactulose), Miralax, Glycolax (polyethylene glycol). The medication is available in a variety of brand names which enables to draw water into the bowel to soften and loosen the stool. However, the medicine may cause side effects such as gas, diarrhea, upset stomach, and stomach cramps.
For this study, the global Chronic Idiopathic Constipation (CIC) Drugs market is categorized into:
- North America (the US and Canada)
- Europe (UK, Germany, and Rest of Europe)
- Asia Pacific (China, Japan, and Rest of Asia Pacific)
- Rest of the World (the Middle East and Africa, and Latin America)
North America led the global CIC drugs market and was valued at USD 767.7 Mn in 2015. Functional disorders such as IBS and CIC affect a large section of the North American population. A large senior population pool and higher reference to professional assistance for treating conditions will contribute to the growth in demand for prescribed CIC drugs in North America. Additional studies have also reported that patient distribution of CIC varies across North America and intensifies in rural and distant regions. Hence, the North American market anticipated further demand for efficient CIC drugs in these regions. US is the largest CIC drug market in North America and worldwide.
The CIC drugs market has been steadily growing in Europe. National governments in the region are perpetually evolving and are striving toward toning down the administration cost and attending time. This has created a need for novel, cost-effective and safer drugs for treating CIC.
The drug market has steady growth in this region as the government is continuously involved in taking initiatives and steps to treat and improve the healthcare segment of the society by providing the latest technological and advanced medication treatment support.
Based on prescription type, the global chronic idiopathic constipation (CIC) drugs market is segmented into the prescription and OTC drugs markets. Furthermore, the prescribed CIC drugs market is further studied for generic and branded OIC drugs.Constipation is never considered a disease but a syndrome or a side effect; people are less likely to visit doctors to get a prescription for constipation. Thus, the CIC drugs market is dominated by over-the-counter prescriptions, with over 50% market share in 2014. The OTC drugs market will continue to dominate the market, growing at the highest CAGR during 2016-2022.
Over-the-counter fiber products such as psyllium (brand name Metamucil), polycarbophil (FiberCon), and methylcellulose (Citrucel) are usually the best first choice for constipation. Higher preference for OTC drugs is a big trend in developing markets of the Asia Pacific and the rest of the world. The same trend is expected to continue during the forecast period in the mentioned regional markets.
